ProfileGDS5678 / 1416824_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 77% 80% 82% 79% 81% 75% 74% 77% 83% 80% 78% 79% 78% 81% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.2203877
GSM967853U87-EV human glioblastoma xenograft - Control 25.7158580
GSM967854U87-EV human glioblastoma xenograft - Control 35.952382
GSM967855U87-EV human glioblastoma xenograft - Control 45.6382679
GSM967856U87-EV human glioblastoma xenograft - Control 55.8028781
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.8180375
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.7614574
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.2745777
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.0196583
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.6745380
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.4279578
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.6267879
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.3328678
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.7924881